Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHP Protonix OTC Switch Considered As Long-Term Possibility

This article was originally published in The Tan Sheet

Executive Summary

American Home Products is interested in the Rx-to-OTC switch possibilities of its proton pump inhibitor Protonix but is unlikely to pursue nonprescription status for the drug in the near-term.

You may also be interested in...



McNeil Supplements Nutritionals Portfolio With Viactiv

Johnson & Johnson's Viactiv acquisition adds a popular calcium supplement to its nascent McNeil Nutritionals division of niche products.

Solgar

Company introduces 23rd product in FemFocus line with Daily Gold Pack for Women, a seven-pill, individually packaged regimen rolled out at NNFA trade show. Available in box of 30 daily packets, new offering comes with suggested retail price of $49.90 and includes Solgar's VM-75 Daily Multiple, Black Cohosh Root Extract, Omega-3 "700" and Vitamin E 200 IU. Entire FemFocus line also will begin implementing packaging changes, with structure/function claims soon to begin appearing in a band on the PDP, Solgar noted. Firm stated all new items targeting women will be part of FemFocus line

OTC Prilosec For Chronic Use Needs Explicit Labeling, NDAC, GDAC Advise

Chronic use of OTC Prilosec (omeprazole) may benefit patients with gastroesophageal reflux disease provided labeling explicitly lists appropriate warnings, advisory committee members concluded at a switch review for the heartburn drug.

Related Content

Topics

UsernamePublicRestriction

Register

PS092832

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel